A-TYPE PROCYANIDINS AND COX-2 EXPRESSION

FIELD OF THE INVENTION

This invention relates to compositions, and methods of use thereof, containing certain polyphenols such as A-type procyanidins and derivatives thereof for treating and/or preventing certain tumors, and more specifically it is directed to methods of treating and/or preventing cancers involving the overexpression of cycloxygenase-2 (COX-2) gene.

BACKGROUND OF THE INVENTION The A-type procyanidins have attracted a great deal of attention in the fields of medicine and nutrition due to the wide range of their biological activities (e.g. U. S.

Pat. App. Pub. No. 20050164956). Applicants have now discovered specific anti-tumor including anti-cancer properties of A-type procyanidins and derivatives thereof and their effect on cyclooxygenase-2 (COX-2) transcription, a key regulating enzyme in the synthesis of prostaglandins humans and other mammals. At least two distinct isoforms of cyclooxygenase are known: COX-I and COX-

2. COX-I is constitutively expressed in many tissues while COX-2 is not normally expressed by most tissues, but is induced rapidly and transiently by proinflammatory mediators and mitogenic stimuli including cytokines, growth factors and tumor promoters. Up-regulation of COX-2 expression is observed at sites of inflammation, in some tumors and under certain physiologic conditions.

An abnormally elevated level of COX-2 is implicated in the pathogenesis of several types of human/mammalian cancers (e. g. colorectal adenocarcinoma, stomach cancer, esophageal cancer, pancreatic cancer, breast cancer, ovarian cancer, cervical cancer, uterine cancer, endometrial cancer, thyroid cancer, urinary bladder cancer, prostate cancer, skin cancer, lung cancer, oral leukoplakia- a precursor lesion of oral cancer, liver cancer, liver metastases from colon cancer, bone metastases, cholangiosarcoma- a highly malignant epithelial neoplasm arising within the biliary

tract, teratocarcinomas, head and neck cancers, lymphomas and leukemias) (Mohan and Epstein, Oral. Oncol, 39: 537-546, 2003). It should be noted that COX-2 overexpression is not seen in every patient with the above-mentioned cancers. COX-2 positive tumors tend to be larger, higher grade, and more likely to spread/metastasize. (Bundred and Barnes, Br. J. Cancer, 93 Suppl 1 :S10-5, 2005; Munkarah and Ali-Fehmi, Curr. Opin. Obstet. Gynecol., 17(l):49-532005). COX-2 expression by tumors is associated with poor prognosis. Women with gynecological tumors overexpressing COX-2 have been shown to have a lower response to standard therapy and shorter survival times (Munkarah and Ali-Fehmi, Curr ^' . Opin. Obstet. Gynecol., 17(1):49- 532005). Further, mice genetically engineered to overexpress COX-2 are found to be susceptible to tumorigenesis (Muller-Decker et al., Proc. Natl. Acad. Sci. U.S.A. 99: 12483-12488, 2002) and conversely, knockout of COX-2 results in altered epidermal differentiation and reduced tumor progression (Tiano et al.,Cancer Res. 62: 3395-3401, 2002). Thus, COX-2 is recognized as a molecular target for tumor therapy (Surh, Food

Chem. Toxicol., 40: 1091-1097, 2002; Surh et al, Mutat. Res. 480^181: 243-268, 2001). At present, there is a need in the art for compounds that can target COX-2 overexpression, particularly at the transcriptional level, in order to prevent and/or treat proliferative growth. It has now been found that compounds of this invention and compositions thereof are effective for such uses. Most of the previously-known COX-2 inhibitors work primarily by blocking COX-2 enzyme activity either directly or indirectly. A disadvantage of inhibition at the enzyme level is that the loss of COX-2 enzyme activity is compensated for (by the body's natural response) by a bio-feedback loop which leads to an increased production of enzyme. The present inventive compounds offer a clear advantage as COX-2 synthesis is inhibited at the level of gene transcription thereby circumventing the formation of additional, undesirable COX-2 via the biofeedback loop mechanism.

SUMMARY OF THE INVENTION

The invention relates to compositions, products and methods for treatment/prophylaxis of certain tumors, particularly certain cancers, and more specifically treatment/prophylaxis of tumors/cancers overexpressing COX-2.

In one aspect, the invention relates to a composition, such as a pharmaceutical, a food, a food additive, or a dietary supplement comprising the compound of the invention such as an A-type procyanidin or a derivative thereof. The composition may optionally contain an additional chemotherapeutic agent, or may be administered in combination with an additional chemotherapeutic agent. Packaged products containing the above-mentioned compositions and a label and/or instructions for use as described herein, e.g. to treat/prevent COX-2-overexpressing tumors/cancers are also within the scope of the invention.

In another aspect, the invention relates to a method of treating or preventing a COX-2 overexpressing tumor, including COX-2 overexpressing cancer, by administering to a mammal, such as a human or a veterinary animal, an effective amount of a compound of the invention such as an A-type procyanidin or a derivative thereof. Non-limiting examples of cancers are colorectal adenocarcinoma, stomach cancer, esophageal cancer, pancreatic cancer, breast cancer, ovarian cancer, cervical cancer, uterine cancer, endometrial cancer, thyroid cancer, urinary bladder cancer, prostate cancer, skin cancer, lung cancer, oral leukoplakia- a precursor lesion of oral cancer, liver cancer, liver metastases from colon cancer, bone metastases, cholangiosarcoma- a highly malignant epithelial neoplasm arising within the biliary tract, teratocarcinomas, head and neck cancers, lymphomas and leukemias, which overexpress COX-2.

In a further aspect, the invention relates to a method comprising (i) profiling a subject for the overexpression of COX-2 and (ii) treating the subject exhibiting overexpression of COX-2 by administering an effective amount of the compounds of the invention.

BRIEF DESCRIPTION OF THE DRAWINGS

FIGURE 1 A-C show the effects of Al dimer in comparison with Bl dimer, B2 dimer, (-)-catechin and (+)-epicatechin (lOμM) on the mRNA expression of COX-2 in LPS and fMLP-pretreated macrophages, and their potency comparison. n=3-4, Mean ± SD. **P<0.01 versus control, ##P<0.01 versus LPS, $$P<0.01 versus LPS + fMLP. The normal macrophages without LPS or fMLP treatment were considered as controls.

DETAILED DESCRIPTION

All patents, patent applications and references cited in this application are hereby incorporated herein by reference. In case of any inconsistency, the present disclosure governs. The invention relates to compositions comprising an effective amount of an A- type procyanidin, or a pharmaceutically acceptable salt or derivative thereof.

The present invention relates to a compound, and a composition comprising an effective amount of the compound which is an oligomer composed of n monomeric, flavan-3-ol units, which has the following formula:

wherein

(i) the monomeric units are connected via interflavan linkages 4→6 and/or 4→8;

(ii) at least two of the monomeric units are additionally linked by an A-type interflavan linkage (4→8; 2→O→7) or (4→6; 2→O→7); and (iϋ) n is 2 to 12; or a pharmaceutically acceptable salt or derivative thereof.

It will be understood by a person of skill in the art that one of the two flavanol units linked by the A-type interflavanoid linkage must comprise two bonds at the 2- and 4-positions. Both of these have either α or β stereochemistry, i.e., the bonds are either 2α, 4α or 2β, 4β. These bonds connect to the 6- and 7-0-positions, or the 8- and 7-0- positions of the second flavanol unit linked by the A-type interflavan linkage. In constituent flavanol units of the oligomer which do not comprise A-type interflavan linkages at positions C-2 and C-4, the linkage at position C-4 can have either alpha or beta stereochemistry. The OH group at position C-3 of flavanol units has either alpha or beta stereochemistry. Flavan-3-ol (monomeric) units may be (+)-catechin or (-)- epicatechin.

An A-type procyanidin as defined above may be derivatized, for instance esterified, at one or more of the OH groups on one or more of the constituent flavan-3- ol units. A given flavan-3-ol unit may thus comprise one or more ester groups, preferably gallate ester groups, at one or more of the 3-, 5-, 7-, 3'- and 4'- ring positions. It may in particular be a mono-, di-, tri-, tetra- or penta-gallated unit.

Examples of the compounds useful for products, and in the methods of the present invention, include the compounds wherein the integer n is 3 to 12; 4 to 12; 5 to 12; 4 to 10; or 5 to 10. In some embodiments, n is 2 to 4, or 2 to 5, for example n is 2 or 3.

In one embodiment, the invention relates to epicatechin-(4β→8; 2β→O→7)- catechin (i.e., Al diiner), or a pharmaceutically acceptable salt or derivative thereof, which Al dimer has the following formula:

In another embodiment, the invention relates to epicatechin-(4β→8; 2β→O→7)-epicatechin (i.e., A2 dimer), or a pharmaceutically acceptable salt or derivative thereof, which A2 has the following formula:

In yet another embodiment, the invention relates to A-type trimer, or a pharmaceutically acceptable salt or derivative thereof, which may have the following formula:

Methods of Use

The invention relates to methods for prevention and/or treatment of certain tumors, particularly certain cancers, and more specifically tumors e.g. cancers that overexpress COX-2 (COX-2 overexpressing tumors/cancers). Non-limiting examples of COX-2 overexpressing cancers to be prevented/treated according to the methods described herein are COX-2 overexpressing colorectal adenocarcinoma, COX-2 overexpressing cancers of the digestive tract (e.g. COX-2 overexpressing stomach cancer, COX-2 overexpressing esophageal cancer and COX-2 overexpressing pancreatic cancer), COX-2 overexpressing breast cancer, COX-2 overexpressing gynecological cancers (e.g. COX-2 overexpressing ovarian cancer, COX-2 overexpressing cervical cancer, COX-2 overexpressing uterine cancer, COX-2 overexpressing endometrial cancer), COX-2 overexpressing thyroid cancer, COX-2 overexpressing urinary bladder cancer, COX-2 overexpressing prostate cancer, COX-2 overexpressing skin cancer; COX-2 overexpressing lung cancer; COX-2 overexpressing oral leukoplakia (a precursor lesion of oral cancer); COX-2 overexpressing liver cancer and liver metastases from colon cancer; COX-2 overexpressing cholangiosarcoma (a highly malignant epithelial neoplasm arising within the biliary tract); COX-2 overexpressing bone metastases; COX-2 overexpressing teratocarcinomas;COX-2 overexpressing head and neck cancers; and COX-2 overexpressing leukemias and lymphomas. Any of the compounds described in the application may be used to practice the methods described herein.

In certain embodiments, the invention provides a method of treating or preventing a COX-2 overexpressing tumor/cancer which comprises administering to a

JatoMM;aiMfetorifa^;ffliitifflf.ili need thereof an effective amount of a compound, or a composition comprising an effective amount of the compound, which is an oligomer composed of n monomeric, flavan-3-ol units of the formula:

wherein

(i) the monomeric units are connected via interflavan linkages 4→6 and/or 4→8;

(ii) at least two of the monomeric units are additionally linked by an A-type interflavan linkage (4→8; 2→O→7) or (4→6; 2→O→7); and (iii) n is 2 to 12; or a pharmaceutically acceptable salt or derivative thereof.

It will be understood by a person of skill in the art that all compounds described in this application can be used for treatment or prevention of a COX-2 overexpressing tumor/cancer. Examples of the compounds useful for products, and in the methods of the present invention, include the compounds wherein the integer n is 3 to 12; 4 to 12; 5 to

12; 4 to 10; or 5 to 10. In some embodiments, n is 2 to 4, or 2 to 5, for example n is 2 or 3.

In one embodiment, a method of treating or preventing a COX-2 overexpressing tumor/cancer comprises administering to a human or a veterinary animal in need thereof an effective amount of an A-type procyanidin which is epicatechin-(4β→8;

2β→O→7)-catechin (i.e., Al dimer), or a pharmaceutically acceptable salt or derivative thereof, and which Al dimer has the following formula:

In another embodiment, a method of treating or preventing a COX-2 overexpressing tumor/cancer comprises administering to a human or a veterinary animal in need thereof an effective amount of an the A-type procyanidin which is epicatechin-(4β-→8; 2β-→O→7)-epicatechin (i.e., A2 dimer), or a pharmaceutically acceptable salt or derivative thereof, which Al has the following formula:

In yet another embodiment, a method of treating or preventing a COX-2 overexpressing tumor/cancer comprises administering to a human or a veterinary animal in need thereof an effective amount of an A-type procyanidin which is an A- type trimer, or a pharmaceutically acceptable salt or derivative thereof, and which A- type trimer may have the following formula:

As used herein, "treatment" means improving an existing medical condition, for example a COX-2 overexpressing tumor/ cancer, for example by slowing down the disease progression, prolonging survival, reducing the risk of death, and/or inducing a measurable reduction in tumor size. Examples of tumors to be treated are colorectal adenocarcinoma, stomach cancer, esophageal cancer, pancreatic cancer, breast cancer, ovarian cancer, cervical cancer, uterine cancer, endometrial cancer, thyroid cancer, urinary bladder cancer, prostate cancer, skin cancer, lung cancer, oral leukoplakia- a precurosor lesion of oral cancer, liver cancer, liver metastases from colon cancer, bone metastases, cholangiosarcoma- a highly malignant epithelial neoplasm arising within the biliary tract, teratocarcinomas, head and neck cancers, lymphomas and leukemias, each overexpressing COX-2. Patients that overexpress COX-2 can benefit from treatment with the present compounds because COX-2 overexpression is often correlated with more aggressive tumors with poor prognosis.

The present compounds are also suitable for combination therapy with other COX-2 specific inhibitors, most of which primarily target the active COX-2 enzyme. Examples of COX-2 inhibitors include meloxicam, etodolac, nimesulide, flosulide, lumiracoxib, celecoxib, valdecoxib, rofecoxib, deracoxib, parecoxib, etoricoxib, darbufelone, and meclofenamate esters and amides.

The present compounds may be administered, in some embodiments, in combination with and/or to enhance responsiveness to chemotherapeutic agents and/or methods. Examples of such agents include: alkylating agents (e.g. busulfan, cyclophosphamide, melphalan); nitrosureas (e.g. carmustine, lomustine); antimetabolites (e.g. 5-fluorouracil, methotrexate, fludarabine); antitumor antibiotics (e.g. bleomycin, doxorubicin) and mitotic inhibitors (e.g. docetaxel, etoposide,

vinorelbine). For that purpose, dosage forms other than pharmaceuticals, e.g. dietary supplements and foods, may also be used.

The invention also encompasses a method of preventing COX-2 overexpressing tumor, particularly COX-2 overexpressing cancer (chemoprevention) comprising administering the compound of the invention to a subject at risk of developing a COX-2 overexpressing tumor/cancer.

The term "preventing" means reducing the risks associated with developing a disease, including reducing the onset of the disease or recurrence of the disease.

The phrase "subject at risk of developing tumor (e.g. cancer)" means a subject with a characteristic(s) which increases the likelihood of tumor (e. g. cancer) in a group of people who have a risk factor for developing the tumor compared to an otherwise healthy group of people who do not. Risk factors may include familial history of COX- 2 overexpressing cancers [e.g. colorectal cancers such as Familial Adenomatous Polyposis (FAP) and Hereditary Nonpolyposis Colorectal Cancer (HNPCC) or Familial Juvenile Polyposis (FJP), an inherited cancer of the gastrointestinal tract]. The importance of COX-2 inhibition in these forms of cancers has been underscored by recent clinical studies using specific COX-2 inhibitors (e.g. rofecoxib, celecoxib) which have shown that these compounds can: (i) reduce intestinal polyp burden in patients with FAP; (ii) prevent the occurrence and/or recurrence of colorectal adenomas and cancers. (Peek, Cancer Chemother. Pharmacol, 54 Suppll :S50-6, 2004).

Chemoprevention is particularly important for such high-risk patients e.g. FAP patients, nearly all whom develop colorectal cancer by age 40, if they hadn't previously undergone polypectomy. (Thompson, Am. J. Health-Syst. Pharm., 62:890-894, 2005). The methods described herein may be used in a human or a veterinary animal, such as a dog, a cat, and a horse.

Thus, the following uses are within the scope of the invention. Use of the compounds of the invention or a pharmaceutically acceptable salt or derivative thereof, as defined above, in the manufacture of a medicament, food, nutraceutical or dietary supplement for inhibiting COX-2 expression. Use of a compounds of the invention or a pharmaceutically acceptable salt or derivative thereof, as defined herein, in the manufacture of a medicament, food, nutraceutical or dietary supplement for use in treating or preventing COX-2 overexpressing tumors e.g. cancers.

The above described methods may further comprise determining the effectiveness of the treatment or prophylaxis, for example, by measuring the level of COX-2 expression in a tissue sample using techniques known in the art.

The advantage of the present invention is that it can offer a personalized medicine approach to the treatment/prophylaxis of tumors particularly cancers. Each patient can be evaluated for his/her expression of COX-2. Thus, methods of profiling of the patients and their subsequent treatment/prophylaxis are also within the scope of the invention. Such method comprises (i) profiling a subject for the overexpression of COX-2 and (ii) treating the subject exhibiting overexpression of COX-2 by administering an effective amount of the compound of the invention.

It will be understood by a person of skill in the art that overexpression in subjects to be profiled and/or treated can be determined using methods and reagents well known in the art. For example, overexpression at the level of transcription can be assessed using Southern and Northern blotting with appropriate nucleic acid probes or by using Polymerase Chain Reaction (PCR).

The effective amount may be determined by a person of skill in the art using the guidance provided herein and general knowledge in the art. For example, the effective amount may be such as to achieve a physiologically relevant concentration in the body of a mammal. Such a physiologically relevant concentration may be at least 20 nanomolar (nM), preferably at least about 100 nM, and more preferably at least about 500 nM. In one embodiment, at least about one micromole in the blood of the mammal, such as a human, is achieved. The compounds of the invention, as defined herein, may be administered at from about 50 mg/day to about 1000 mg/day, preferably from about 100-150 mg/day to about 900 mg/day, and most preferably from about 300 mg/day to about 500 mg/day. However, amounts higher than stated above may be used. The amounts may be measured as described in Adamson, G.E. et al., J. Ag. Food Chem.; 1999; 47 (10) 4184-4188.

The treatments/preventive administration may be continued as a regimen, i.e., for an effective period of time, e.g., daily, monthly, bimonthly, biannually, annually, or in some other regimen, as determined by the skilled medical practitioner for such time as is necessary. The administration may be continued for at least a period of time required to reduce COX-2 expression to therapeutically relevant levels. Preferably, the composition is administered daily, most preferably two or three times a day, for

example, morning and evening to maintain the levels of the effective compounds in the body of the mammal. To obtain the most beneficial results, the composition may be administered for at least about 30, or at least about 60 days. These regiments may be repeated periodically.

Compositions and Formulations

The compounds of the invention may be administered as a pharmaceutical, a food, a food additive, or a dietary supplement.

As used herein, a "pharmaceutical" is a medicinal drug. See Merriam- Webster's Collegiate Dictionary, 10th Edition, 1993. A pharmaceutical may also be referred to as a medicament. A "food" is a material containing protein, carbohydrate and/or fat, which is used in the body of an organism to sustain growth, repair and vital processes and to furnish energy. Foods may also contain supplementary substances, for example, minerals, vitamins and condiments. See Merriam- Webster's Collegiate Dictionary, 10th Edition, 1993. The term food includes a beverage adapted for human or animal consumption. As used herein a "food additive" is as defined by the FDA in 21 C.F.R. 170.3(e)(l) and includes direct and indirect additives. As used herein, a "dietary supplement" is a product (other than tobacco) that is intended to supplement the diet that bears or contains the one or more of the following dietary ingredients: a vitamin, a mineral, an herb or other botanical, an amino acid, a dietary substance for use by man to supplement the diet by increasing the total daily intake, or a concentrate, metabolite, constituent, extract or combination of these ingredients. The above compositions may be prepared as is known in the art.

The compositions may contain a carrier, a diluent, or an excipient. Depending on the intended use, the carrier, diluent, or excipient may be chosen to be suitable for human or veterinary use, food, additive, dietary supplement or pharmaceutical use. The composition may optionally contain an additional tumor/cancer treating agent. Also depending on use, a person of skill in the art may select the degree of purity of the compound of the invention. For example, when used to prepare pharmaceutical dosage forms, the compound should be as pure as commercially possible, while when preparing food, additive, or supplement, less pure or mixtures of compounds (e.g. plant extracts) may be used.

The compound of the invention may be "isolated and purified," i.e., it may be separated from compounds with which it naturally occurs (e.g. when the compound is of natural origin), or it may be synthetically prepared, in either case such that the level of contaminating compounds and/or impurities does not significantly contribute to, or detract from, the effectiveness of the compound. For example, an "isolated and purified Aldimer" is separated from A2 dimer, with which it may occur in nature (e.g. peanut skins, cranberries) to the extent achievable by the available commercially viable purification and separation techniques. Such compounds are particularly suitable for pharmaceutical applications. The compound may also be less pure, i.e., "substantially pure," i.e., it may possess the highest degree of homogeneity achievable by available purification, separation and/or synthesis technology but need not be separated from the like compounds. As used herein, "the like compounds" are the compounds having the same degree of polymerization. For example, a "substantially pure dimer" refers to a mixture of dimers (e.g. Al and A2, as it would occur in a "plant extract fraction"). While less suitable for pharmaceutical applications, such "substantially pure" compounds may be utilized for food, food additive and dietary supplement applications.

In some embodiments, the compound of the invention is at least 80% pure, at least 85% pure, at least 90% pure, at least 95% pure, at least 98% pure, or at least 99% pure. Such compounds are particularly suitable for pharmaceutical applications.

Pharmaceuticals containing the inventive compounds, optionally in combination with another cancer treating agent, may be administered in a variety of ways such as orally, sublingually, bucally, nasally, rectally, intravenously, parenterally and topically. A person of skill in the art will be able to determine a suitable mode of administration to maximize the delivery of the compounds of the invention, and optionally another cancer treating agent, to the site of the tumor. Thus, dosage forms adapted for each type of administration are within the scope of the invention and include solid, liquid and semi-solid dosage forms, such as tablets, capsules, gelatin capsules (gelcaps), bulk or unit dose powders or granules, emulsions, suspensions, pastes, creams, gels, foams or jellies. Sustained-release dosage forms are also within the scope of the invention. Suitable pharmaceutically acceptable carriers, diluents, or excipients are generally known in the art and can be determined readily by a person skilled in the art. The tablet, for example, may comprise an effective amount of the compound of the

invention and optionally a carrier, such as sorbitol, lactose, cellulose, or dicalcium phosphate.

The foods comprising the compounds described herein and optionally another tumor/cancer treating/preventing agent may be adapted for human or veterinary use, and include pet foods. The food may be other than a confectionery, for example, a beverage (e.g. cocoa flavored beverage). A confectionery such as a standard of identity (SOI) and non-SOI chocolate, such as milk, sweet and semi-sweet chocolate including dark chocolate, low fat chocolate and a candy which may be a chocolate covered candy are also within the scope of the invention. Other examples include a baked product (e.g. brownie, baked snack, cookie, biscuit) a condiment, a granola bar, a toffee chew, a meal replacement bar, a spread, a syrup, a powder beverage mix, a cocoa or a chocolate flavored beverage, a pudding, a rice cake, a rice mix, a savory sauce and the like. If desired, the foods may be chocolate or cocoa flavored. Food products may be chocolates and candy bars, such as granola bars, containing nuts, for example, peanuts, walnuts, almonds, and hazelnuts.

A-tyρe procyanidins may be of natural origin or synthetically prepared. For example, A-type procyanidins may be isolated from peanut skins as described in Lou et al, Phytochemistry, 51: 297-308 (1999), or Karchesy and Hemingway, J. Agric. Food Chem., 34:966-970 (1986), the relevant portions of each being hereby incorporated herein by reference. Mature red peanut skin contain about 17% by weight procyanidins, and among the dimeric procyanidins epicatechin-(4β→8; 2β→O→7)- catechin dominates, with smaller proportion of epicatechin-(4β→8; 2β→O→7)- epicatechin being present. However, in addition to A-type procyanidins having (4— »8; 2→O→7) double linkages, procyanidins having (4-→6; 2→O→7) double linkages are also found in peanut skins.

Other sources of the above compounds are cranberries as described, for example in Foo et al, J. Nat. Prod., 63: 1225-1228, and in Prior et al, J. Agricultural Food Chem., 49(3):1270-76 (2001), the relevant portions of each being hereby incorporated herein by reference. Other sources include Ecdysanthera utilis (Lie-Chwen et al, J. Nat. Prod, 65:505-8 (2002)) and Aesculus hippocastanum (U.S. Pat. No. 4,863,956), the relevant portions of each being hereby incorporated herein by reference.

A-type compounds may also be obtained from B-type procyanidins via oxidation using l,l-diphenyl-2-pycrylhydrazyl (DPPH) radicals under neutral

conditions as described in Kondo et al, Tetrahedron Lett., 41 : 485 (2000), the relevant portions of which are hereby incorporated herein by reference. Methods of obtaining natural and synthetic B-type procyanidins are well known in the art and are described, for example, in U.S. Pat. Nos. 6,670,390 to Romanczyk et al; 6,207,842 to Romanczyk et ah; 6,420,572 to Romanczyk et al ; and 6,156,912 to Romanczyk et al

The A-type procyanidins may be used in the compositions described herein and administered in the form of an extract (e.g. peanut skins extract) comprising A-type procyanidins as the main component.

A daily effective amount of the compound of the invention may be provided in a single serving in case of a food or a single dosage in case of a pharmaceutical or a dietary supplement. For example, a confectionery (e.g. chocolate) may contain at least about 100 mg/serving (e.g. 150-200, 200-400 mg/serving).

The dietary supplement containing the compounds of the invention, and optionally another cancer treating agent, may be prepared using methods known in the art and may comprise, for example, nutrients such as dicalcium phosphate, magnesium stearate, calcium nitrate, vitamins, and minerals.

Further within the scope of the invention is an article of manufacture such as a packaged product comprising the composition of the invention (e.g. a food, a dietary supplement, a pharmaceutical) and a label indicating the presence of, or an enhanced content of the inventive compounds or directing use of the composition to treat a COX- 2 expressing tumor (e.g. cancer). The packaged product may contain the composition and the instructions for use to treat a COX-2 overexpressing tumor (e.g. cancer). The label and/or instructions for use may refer to any of the methods of use described in this application. In certain embodiments, the label and/or the instructions for use direct use of the compounds of the invention for treating COX-2 overexpressing tumors.

The invention also relates to a method of manufacturing an article of manufacture comprising any of the compositions described herein, packaging the composition to obtain an article of manufacture and instructing, directing or promoting the use of the composition/article of manufacture for any of the uses described herein. Such instructing, directing or promoting includes advertising.

The invention is further described in the following non-limiting examples.

EXAMPLES

Example 1; Effect of Proevanidins Al and A2 on Cox-2 expression

Materials

Procyanidin dimers Al and A2 are obtained. Phorbol 12-myristate 13 -acetate (PMA) ₅ Lipopolysaccharides (LPS ₅ from Escherichia coli serotype 0111 : B4) and NS398 are purchased from Sigma (St. Louis, MO). RPMI 1640, L-glutamine, HEPES ₅ 2-mercaptoethanol ₅ fetal bovine serum, and penicillin/streptomycin are purchased from Gibco BRL (Grand Island, NY). Anti-COX-2 is purchased from Santa Cruz Biotechnology Inc (Santa Cruz, CA). SuperSignal West Pico chemilurninescent substrate and. PGE ₂ -specific RIA kit are purchased from Beijing East Asia Institute of Immunology (Beijing CN). AU other chemicals used are in the purest form available commercially.

Cell culture

Human monocytic THP-I cells (American Type Culture Collection, Manassas, VA) in RPMI 1640 medium (Life Technologies, Rockville, MD) ₅ with 4.5 g/L glucose, 10 mM HEPES ₅ 1 mM sodium pyruvate, and 50 μM 2-ME supplemented with 10% FBS, are cultured under a humidified 5% CO ₂ atmosphere at 37 °C. For differentiation, THP-I cells are plated at IxIO ⁶ cells/ml in the medium containing 100 nM PMA and allowed to adhere for 48 h, after which they are fed with PMA-free medium and cultured for 24 h prior to use. LPS is used at concentration of lμg/ml in the medium. sf9 cells are cultured in monolayer at 28 ⁰ C in Grace's supplemented medium with 10 % heat- inactivated fetal bovine serum.

Determination of COX-2 Enzyme Activity

The effect of procyanidin dimers Al and A2, andNS398 on the activity of COX-2 is measured using baculovirus-expressed recombinant human COX-2 enzyme as previously described (Zhang et al., Acta. Pharmacol. Sin. 25(8):1000-1006, 2004). Briefly, 24 h after infecting sf9 cells with hCOX-2 recombinant baculovirus, the cells are collected and washed in HHBC. The assays are performed as follows. One milliliter of Hank's solution containing 1x10 ⁵ COX-2 expressing cells plus 9x10 ⁵ uninfected sf9

cells is dispensed per well of 24-well polypropylene plates. Inhibitor or DMSO vehicle (10 μL) is added to the appropriate well containing the cell suspension. Following a 15- min drug or DMSO preincubation at 37 ⁰ C ₅ the cells are challenged with 10 μmol/L arachidonic acid (Sigma) in ethanol and incubated for 10 min. Reactions are terminated by the addition of 100 μL of 1 mol/L HCl, neutralized with 100 μL of 1 mol/L NaOH. The cells are pelleted for 10 min at 300xg and the level of PGE ₂ in the supernatant is determined by a PGE ₂ -specific RIA (Beijing East Asia Institute of Immunology). The concentration OfPGE ₂ is then determined by interpolation from a standard curve and inhibition is calculated by comparison of the PGE ₂ production by drug-treated cells with that of DMSO-treated cells.

Real-time quantitative reverse transcriptase-polymerase chain reaction (RT-PCR) to assess COX-2 mRNA expression

Total RNA is extracted from macrophages with TRIzol reagent. Real-time quantitative RT-PCR is performed using the Opticon 2 (MJ Research Inc., Waltham, MA). Sequence specific PCR primers for COX-2 [accession no. NM_000963; forward primer: 5'-GGGCAAAGACTGCGAAGAAG-S' [SEQ ID NO: I]; reverse primer: 5'- CCCATGTGACGAAATGACTG-3' [SEQ ID NO: 2]] and GAPDH [accession no. NM_002046; forward primer: 5'-ACGGATTTGGTCGTATTGGG-S' [SEQ ID NO: 3]; reverse primer: 5 '-CGCTCCTGGAAGATGGTGAT-3 ' [SEQ ID NO: 4]] are designed using the Primer Premier software version 5.00. Standard curves are run on the same plate and the relative standard curve method is used to calculate the relative gene expression.

Western Blot analysis

5x10 ⁶ cells are resuspended in modified RIPA lysis buffer (Tris-HCl 50 mM, pH 7.4 NaCl 150 mM, EDTA 1 mM, Na-deoxycholate 0.25%, NP-40 1%, PMSF 1 mM, Na ₃ VO4 1 mM, NaF 1 mM, Aprotinin 10 μg/ml, leupeptin 5 μg/ml, pepstatin 5 μg/ml), and lysed cells on ice for 45 min. The lysate is centrifuged at 14,000xg for 15 min to sediment the particulate materials. The protein concentration of the supernatant is measured by the method of Lowry (Lowry et al., J. Biol. Chem. 193:265-267, 1951). Samples are electrophoresed in SDS/PAGE gels and separated proteins are transferred

onto a PVDF membrane. The blots are blocked with 5% non-fat dry milk in Tris- buffered saline (TBS) for 1 h at room temperature and subsequently incubated overnight at 4 °C with primary antibodies diluted (1 :1000) in TBST [TBS, 1% (v/v) Tween 20 and 5% (w/v) BSA]. Following three washes of 10 min each with TBST, the blots are incubated with horseradish peroxidase-conjugated secondary antibodies in blocking buffer for 1 h at room temperature. After three washes with TBST, the blots are developed with chemiluminescence reagent and exposed to X-ray film (Kodak XAR5, Eastman Kodak, Rochester, NY, U.S.A.).

Example 2: Effect of procyanidin dimer Al in comparison with Bl dimer, B2 dimer and flavanols ((-)- catechin and (+)-epicatechm) on COX-2 expression

Materials

Phorbol 12-myristate 13 -acetate (PMA), lipopolysaccharide (LPS), andN-formyl- methionyl-leucyl-phenylalanine (fMLP), were obtained from Sigma (St. Louis, MO). Chemicals employed for gel electrophoresis were purchased from Bio-Rad (Hercules, CA). Trypsin sequencing grade was obtained from Promega (Southampton, United Kingdom). EDTA, EGTA, and PMSF were purchased from Amresco (Solon, OH). Al dimer was prepared from peanut skins as described in the U.S. Application Serial No. 11/045,648 (published as US 2005/0164956), which is hereby incorporated herein by reference. Flavanols (+)-catechin and (-)-epicatechin were purchased from Sigma, and (-) catechin and (+)-epicatechin were prepared by thermally-treating (+)-catechin and (- )-epicatechin, respectively, in an aqueous solution as is known in the art. Procyanidin dimer B2 was prepared from cocoa by solvent extraction, using gel permeation chromatography, followed by further purification/isolation of a dimer enriched fraction using Normal-Phase HPLC (described in detail in Adamson et al., J Ag. Food Chem., 1999, 47 (10):4184-4188), see also US Pat No. 5,554,645, both of which are hereby incorporated herein by reference. This material was then passed over a Cl 8 column to further enrich B2 dimer (98.3%) in the fraction which was used in the experiments described below.

Cell Culture, RNA Extraction and Polymerase Chain Reaction (RT-PCR)

The human monocyte line U937 was obtained from the cell bank in Shanghai Institute of Biological Sciences, Chinese Academy of Sciences. Monocytic cells of 3-4 passages were grown to confluence in RPMI 1640 (GIBCO-BRL, Glasgow, Scotland) containing 10 % fetal bovine serum at 37 ⁰ C in a 5 % CO ₂ humidified incubator during all experimental procedures. Macrophages were pretreated with procyanidins Al dimer, Bl dimer, B2 dimer, and flavanols (-)-catechin and (+)-epicatechin (lOμM) for 2 h before LPS (lμg.ml ^"1 ) priming or fMLP (lμM) stimulation for 2 h. The normal macrophages without LPS or fMLP treatment were considered as controls. They were then differentiated to macrophages in the medium containing 100 nM PMA and allowed to adhere for 48 h, after which they were fed with PMA-free medium and cultured for 24 h prior to use. Cells from different groups were collected and total RNA was prepared with TRI-REAGENT-LS extraction kit. The expression of RNAs was determined by RT-PCR. Complementary DNA was created from RNA using TrueScript MMLV reverse transcriptase and oligo d (T) 18 primers. 5 μg RNA was included in each reaction. The primers of COX-2 and GAPDH are shown in the following table.

Products

Gene Name Primer sequnce

(bp)

COX-2 sense: 5'-TATACTAGAGCCCTTCCTCCTGTGCC-S ' [SEQ 503

K) NO: 5] antisense: 5'-ACATCGCATACTCTGTTGTGTTCCC-S' [SEQ ID NO: 6] GAPDH sense: 5'-AAGAAGGTGGTGAAGCAGGC-S' [SEQ ID NO: 200

7] antisense: 5'-CCACCACCCTGTTGCTGTAG-S' [SEQ ID

NO: 8]

Statistical analysis of data.

The data are presented as means ± SD and compared with ANOVA and least significant difference test using SPSS statistical program. The level of the statistical significance was set at P < 0.05.

Results

The anti-inflammatory effects of Al dimer in comparison with Bl dimer, B2 dimer, (-)-catechin and (+)-epicatechin were investigated. As shown in Fig. 1 A-C ₅ (- )-catechin, (+)-epicatechin, Al _, Bl and B2 showed significant inhibition of the mRNA expression of COX-2. Further, the order of suppression potency of the COX-2 mRNA expression induced by LPS and fMLP was: (-)-catechin, (+)-epicatechin > Bl, B2>A1 (Fig. 4C).